AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03342950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Topical Solution of anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
Study NCT01592201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperdidone ER
Description: Form = osmotic release oral system, route = oral
Study NCT01592201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole, olanzapine and risperidone (Antipsychotics)
Description: Form = tablet, route = oral
Study NCT04436276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
Study NCT04436276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo.
Study NCT01933841 — intervention group
Intervention type: DEVICE
Intervention: TOF-Watch SX
Description: As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.
Study NCT01933841 — intervention group
Intervention type: PROCEDURE
Intervention: Notify the provider
Description: Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio.
Study NCT02690194 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: The placebo group will wear headphones and listen to nature sounds.
Study NCT03601962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aqualief
Description: 400mg oral mucoadesive tablets
Study NCT03601962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg Placebo oral mucoadesive tablets
Study NCT02690194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buddhify Therapy
Description: The experimental group will complete a Buddhify relaxation therapy session, before their injection. This therapy consists of wearing headphones and listening to guided meditation instructions.
Study NCT03568877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metabolaid®
Description: 500 mg per day, in fasting conditions.
Study NCT03568877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg per day, in fasting conditions.
Study NCT01292655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-906024
Study NCT03290950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daratumumab
Description: Cycle 1 ONLY: Daratumumab 16 mg/kg days 1, 8, 15, and 22, Cycle 2: Daratumumab 16mg/kg days 1, 8, 15, and 22; Cycles 3-6: Daratumumab 16mg/kg days 1 and 15, Cycles 7-8: Daratumumab 16mg/kg day 1; Daratumumab rate of infusion is per MSKCC guidelines.
Study NCT03290950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 2 and 3; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16; Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
Study NCT03290950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Cycle 1 ONLY: Lenalidomide 25 mg/day, days 2-21 every 28 days; Cycles 2-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
Study NCT03290950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 2, 3, 8, 9, 15, 16, Cycles 2: Dexamethasone 20mg/dose, days 1, 2, 8, 9, 15, 16 and 22; Cycles 3-4: Dexamethasone 20mg/dose, days 1,2,8,9,15 and 16, Cycles 5- 8: Dexamethasone 10mg/dose, days 1, 2, 8, 9, 15, and 16
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Play + Self-Regulation
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum, and an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Play + Parent Education
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Play Only
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Active Play curriculum. Parents will receive access to web-based resources on food literacy.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation + Parent Education
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation Only
Description: In addition to a 27-lesson, core food literacy curriculum that children across all conditions will receive, children in this condition will also be exposed to an 11-lesson Self-Regulation curriculum. Parents will receive access to web-based resources on food literacy.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Literacy + Parent Education
Description: Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy, and will be invited to complete 18 web-based education modules on topics including improving household routines, managing children's behaviors and emotions, improving children's sleep patterns, improving access to healthy foods, healthy meal and snack preparation, modeling healthy eating and activity behaviors, and improving family activity patterns.
Study NCT03290950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 1, 2, 22; 40 mg/dose days 8 and 15, Cycles 2: Dexamethasone 40mg/dose, days 1, 8, 15; 20 mg/dose day 22, Cycles 3-4: Dexamethasone 40mg/dose, Days 1, 8 15, Cycles 5-8: Dexamethasone 20mg/dose, Days 1, 8, 15
Study NCT02946801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Essential oils
Study NCT02946801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils without alcohol
Study NCT02576353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl Sublingual Spray (FSS)
Study NCT02946801 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sterile water
Study NCT01564836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imatinib treatment discontinuing
Description: Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
Study NCT03992144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 Mg
Description: Amoxicillin 500mg an hour before tooth extraction
Study NCT03992144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole 400mg
Description: 400mg of metronidazole an hour before extraction
Study NCT03992144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazol 400mg and amoxicillin 500mg
Description: 400mg metronidazole TDS, amoxicillin 500mg BD for 5 days after extraction
Study NCT03163381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg,po,qd,medicine to disease progression.
Study NCT00797693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol ( Cytotec) 200 microgram a tablet
Description: In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
Study NCT04082208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow nasal cannula
Description: Administration of high flow nasal cannula during ERCP procedure
Study NCT04082208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow nasal cannula
Description: Administration of low flow nasal cannula during ERCP procedure: standard care
Study NCT03064490 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Neoadjuvant Pembrolizumab ( 3 cycles) administered concurrently with weekly Carboplatin and Paclitaxel and daily radiation therapy; followed by surgical resection and adjuvant Pembrolizumab ( 3 cycles)
Study NCT02115230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation + medical therapy
Description: Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
Study NCT02848833 — intervention group
Intervention type: DRUG
Intervention: JARDIANCE 10mg
Description: T2DM with JARDIANCE 10mg
Study NCT02848833 — intervention group
Intervention type: DRUG
Intervention: JARDIANCE 25mg
Description: MT2DM with JARDIANCE 25mgax
Study NCT02576353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: Fentanyl Citrate IV (FCIV)
Study NCT03950973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareAvenue
Description: CareAvenue is an e-health tool providing information about diabetes management and low-cost resources. Participants in this group have access to CareAvenue and receive a weekly automated phone call and text messages related to CareAvenue and its resources as well as diabetes management.
Study NCT03950973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guest Assistance Program
Description: The Guest Assistance Program (GAP) is a resource, which provides assistance with medical and non-medical needs and resources to patients receiving medical care at University of Michigan health system. Participants in this group are provided with GAP information and receive text messages related to diabetes management.
Study NCT04524611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion
Study NCT04524611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) Injection
Study NCT04524611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Intravenous (IV) infusion
Study NCT04524611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Subcutaneous (SC) injection
Study NCT00893464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB
Description: Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
Study NCT01785355 — intervention group
Intervention type: OTHER
Intervention: Dental treatment
Description: 1. The preliminary stage deals with:~   * assessment of the clinical state of the patient by completing a detailed dental and periodontal chart~  * education of the patient regarding correct oral hygiene habits;~2. Phase I Therapy:~   * plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)~  * evaluation of response to the treatment~3. Phase II Therapy - surgical phase:~   * extraction of hopeless teeth~  * evaluation of the surgical results.~4. Maintenance phase:~   * periodic reevaluation of plaque and calculus and of periodontal conditions.
Study NCT02055404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A spherical contact lens with molded marks
Description: Silicone hydrogel contact lens with 9 different molded marks of varying widths and depths indented into the front surface (S1, S2, S3, S4, S5, S6, S7, S8, and S9). Each lens contained all 9 marks.
Study NCT02055404 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A toric contact lens
Description: Hydrogel toric contact lens for daily wear, daily disposable use
Study NCT02113670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUI 1
Description: instillation of 50ml of air into the urinary bladder before the urodynamic test
Study NCT00236080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROVIGIL 200 mg
Description: PROVIGIL 200 mg/day
Study NCT00236080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg
Description: Armodafinil 250 mg/day
Study NCT00236080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 200 mg
Description: Armodafinil 200 mg/day
Study NCT00236080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg
Description: Armodafinil 150 mg/day
Study NCT00236080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study NCT04297462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir 3 days
Description: Non-inferiority study of 3 versus 7-days duration of PEP
Study NCT04297462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir 7 days
Description: Active comparator
Study NCT01214044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/escitalopram
Description: Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
Study NCT02400255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib besylate
Study NCT00599417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacterial Lysates
Description: Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
Study NCT00599417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo controlled
Study NCT02185937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cola
Description: imatinib intake with coca-cola
Study NCT00936988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet
Description: Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
Study NCT04272567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.
Study NCT04272567 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
Study NCT04255667 — intervention group
Intervention type: PROCEDURE
Intervention: Eyelid margin crush
Description: after marking eyelid , hemostat is used for eyelid margin incision crush . Then eyelid surgery is done
Study NCT02714478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: equistasi
Description: 3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
Study NCT02714478 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
Study NCT00464204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 % Hydroxyethylstarch 130/0.4 = Voluven®
Description: Voluven® was administered intravenously. Voluven® rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day on the second to fourth days, according to patient needs.
Study NCT00464204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9 % NaCl
Description: NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
Study NCT01653119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
Study NCT01988389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole apples (WA)
Study NCT01988389 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: apple juice (AJ)
Study NCT04447885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: weighted blanket
Description: A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
Study NCT04447885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: weighted blanket
Description: A weighted blanket is a blanket with extra weight sewn in for added pressure to the body.
Study NCT04552678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Literacy Only
Description: Children in this condition will only receive a 27-lesson, core food literacy curriculum (children across all conditions will receive this curriculum). Parents will receive access to web-based resources on food literacy.
Study NCT04182464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Food additive used to replace sugar providing a sweet taste without calories
Study NCT02069665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fuxiong San
Description: external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily
Study NCT02069665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping injection
Description: ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
Study NCT04182464 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cornstarch without significant physiological effects
Study NCT04090775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Opdivo Injectable Product
Description: Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected.
Study NCT04090775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Yervoy Injectable Product
Description: Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected.
Study NCT04090775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytoxan
Description: Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again.
Study NCT04090775 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryosurgical freezing (cryosurgery)
Description: Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.
Study NCT00441792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Etomidate at induction dose based on weight
Study NCT03373331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Processing Training
Description: Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).